Asthma Market

Key Highlights

• As per Khan et al. (2020), the data from the National Health and Wellness Survey (NHWS) indicates the weighted prevalence of diagnosed asthma as 6.2% among France, Germany, Italy, Spain and the United Kingdom (France 5.3%; Germany 5.9%; UK 9.5%; Italy 4.6%; Spain 5.5%).

• Asthma epidemiology is segmented as Total Asthma Prevalent Cases, Asthma Type-specific Cases, Asthma Gender-specific Cases, Asthma Age-specific Prevalent Cases, Asthma Diagnosed and Treatable Cases in the Asthma market report.

Request for unlock CAGR of Asthma Market

DelveInsight’s “Asthma – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

The Asthma market report provides current treatment practices, emerging drugs, Asthma market share of the individual therapies, and current and forecasted Asthma market size from 2019 to 2032, segmented by seven major markets. The report also covers current Asthma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain), the United Kingdom
• Japan

Study period: 2019–2032

Asthma Market: Understanding and Treatment Algorithm

The DelveInsight’s Asthma market report gives a thorough understanding of Asthma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Asthma is a chronic disease affecting the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Asthma is a heterogeneous disease characterized by episodes of airways narrowing or hyper responsiveness, obstruction, inflammation and mucous production. Asthma clinically presents as wheezing, coughing, chest tightness and shortness of breath. Different inflammatory pathways drive the airway inflammation and hyper responsiveness associated with asthma.

Current evidence suggests that asthma is a complex multifactorial disorder and its etiology is increasingly attributed to interactions between genetic susceptibility, host factors, and environmental exposures. These include environmental factors (air pollution, pollens, mold and other aeroallergens, and weather), host factors (obesity, nutritional factors, infections, allergic sensitization), and genetic factors (asthma susceptibility loci on genes).

Asthma Diagnosis

There is no gold standard single test to diagnose asthma, there are several objective tests that can be used to support the diagnosis including physiological measures such as obstructive spirometry associated with bronchodilator reversibility and airway hyper responsiveness. In addition, non-invasive tests of airway inflammation such as exhaled nitric oxide or peripheral blood eosinophils are important to identify those with an allergic or eosinophilic phenotype.

Asthma Treatment

Current drug treatments for asthma include long-term control treatments, such as inhaled corticosteroids, long-acting beta-agonists, and oral medications. For acute episodes, oral corticosteroids, beta-agonists, and inhaled bronchodilators are used. Environmental control measures (e.g. humidity regulation, vacuuming, and pest management) can reduce asthma exacerbations due to airborne allergens such as tobacco smoke, particulate matter, pollen, mold, or dust mites.

Asthma Epidemiology

The Asthma epidemiology section provides insights into historical and current Asthma patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Asthma report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings

• As per Khan et al. (2020), the data from the National Health and Wellness Survey (NHWS) indicates the weighted prevalence of diagnosed asthma as 6.2% among France, Germany, Italy, Spain and the United Kingdom (France 5.3%; Germany 5.9%; UK 9.5%; Italy 4.6%; Spain 5.5%).

• The epidemiology covered in the report provides historical as well as forecasted patient numbers [segmented as Total Prevalent Cases of Asthma, Type-specific Cases of Asthma, Gender-specific Cases of Asthma, Age-specific Prevalent Cases of Asthma, Diagnosed and Treatable Cases of Asthma] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan from 2019 to 2032.

Country-wise Asthma Epidemiology

The epidemiology segment also provides the Asthma epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Learn more about the evolving epidemiology trends and key developments: Asthma Epidemiology Forecast

Asthma Drug Chapters

The drug chapter segment of the Asthma report encloses the detailed analysis of Asthma marketed drugs and late-stage (Phase III and Phase II) Asthma pipeline drugs. It also helps understand the Asthma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Asthma Drugs

The report details the emerging Asthma therapies under the late and mid-stage of development for Asthma treatment.

Asthma Market Outlook

The Asthma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Asthma market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Asthma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Asthma market in 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Asthma market in 7MM.

The United States: Asthma Market Outlook

This section provides the total Asthma market size and market size by therapies in the United States.

EU4 (Germany, France, Italy, and Spain), the United Kingdom: Asthma Market Outlook

The total Asthma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Asthma Market Outlook

The total Asthma market size and market size by therapies in Japan are also mentioned.

Asthma Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched in the market during the study period 2019–2032. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

This will help in understanding the Asthma drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Asthma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Asthma’s key players involved in developing targeted therapeutics.

Asthma Clinical Trial Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Asthma emerging therapies.

Learn more about the emerging therapies and key companies active in the therapeutics segment: Asthma Pipeline Insight

Asthma Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Asthma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Asthma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Asthma market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Asthma Market Report

• Descriptive overview of Asthma, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies.
• Comprehensive insight into the Asthma epidemiology and forecasts in the 7MM.
• An all-inclusive account of both the current and emerging therapies for Asthma, along with the assessment of new therapies, expected to have an impact on the current treatment landscape.
• Exhaustive analysis of the Asthma market; historical and forecasted covering drug outreach in the 7MM.
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Asthma market.

Asthma Market Report Highlights

• In the coming years, the Asthma market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Asthma therapies. The launch of emerging therapies will significantly impact the Asthma market
• A better understanding of Asthma pathogenesis will also contribute to the development of novel therapeutics for Asthma
• Our in-depth analysis of the Asthma pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Asthma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Asthma Report Insights

• Patient Based Market Forecasting
• Therapeutic approaches
• Asthma pipeline analysis
• Asthma market size and trends
• Asthma market opportunities
• Impact of upcoming therapies

Asthma Report Key Strengths

• 11 years forecast
• 7MM Coverage
• Asthma epidemiology segmentation
• Key cross competition
• KOL views
• Asthma drugs uptake

Asthma Report Assessment

• Current treatment practices
• Unmet needs
• Asthma pipeline product profiles
• Asthma market attractiveness

Key Questions

Asthma market insights:

• What would be the Asthma market growth till 2032, and what will be the resultant market size in 2032?
• What was the Asthma drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Asthma total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Asthma market size during the forecast period (2019–2032)
• How would the unmet needs affect the Asthma market dynamics and subsequent analysis of the associated trends?

Asthma Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Asthma?
• What is the historical and forecasted Asthma patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Asthma in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Asthma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Asthma and its status, along with the challenges faced?

Reasons to Buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Asthma market
• Organize sales and marketing efforts by identifying the best opportunities for Asthma in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors